Prelude Therapeutics Reports Q2 2026 Financial Results

What Happened
Prelude Therapeutics Incorporated announced its quarterly financial results in a press release dated August 11, 2026. The company filed a Form 8-K (Item 2.02) furnishing that press release, which reports results for the three months ended June 30, 2026. The 8-K was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer.

Key Details

• Press release announcing financial results was issued and attached to the 8-K as Exhibit 99.1 on August 11, 2026.
• Reporting period: three months ended June 30, 2026 (Q2 2026).
• The information in the 8-K and Exhibit 99.1 is being furnished, not filed, and thus is not subject to Section 18 filing liabilities nor incorporated by reference into other filings.
• The Form 8-K was executed by Bryant Lim (CFO & CLO).

Why It Matters
Quarterly financial results are a primary source of information about a company’s earnings, revenue trends, cash position, and operational progress. Investors should review the attached press release for the specific financial figures and commentary the company provided for Q2 2026. Note the disclosure is furnished (not filed), which is a legal-formal distinction about incorporation and liability under SEC rules.